Nanexa AB (publ)
Price
Where the revenue goes
Loading the income statement flow…
Where the revenue comes from
Fundamentals
Loading key figures…
Insiders, analysts and people
All trades and changesLoading insiders, analysts and opinions…
Co se právě děje
AI souhrnAbout the company
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
- Website
- nanexa.com
- Employees
- 17
- Country
- Sweden
- Data since
- 17. 6. 2015